Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study
Gerassimos J. Mantzaris(European CanCer Organisation), Andrés Yarur(Cedars-Sinai Medical Center), Brian Bressler(University of British Columbia), Neil R. Brett(McGill University), Michelle Luo(University of North Carolina at Chapel Hill), Shashi Adsul(Takeda (United States)), Chris Colby(Kaiser Permanente), Pravin Kamble(Takeda (United States)), Song Wang(University of Jinan), Sumit Saha(Takeda (Canada))
Cited by 9
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478